We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
依达拉奉右莰醇联合丁苯酞治疗对老年大动脉粥样硬化型脑卒中 患者血清 PTX3、lp-PLA2 以及 MES 的影响.
- Authors
景 燕; 王泽斌; 曾 姗; 陆明佳; 仲 婷; 李红燕
- Abstract
Objective: To investigate the effects of edaravone dexborneol combined with butylphthalide on serum pentraxin 3 (PTX3), lipoprotein associated phospholipase A2 (lp-PLA2) and microembolic signals (MES) in elderly patients with large artery atherosclerosis (LAA) stroke. Methods: A total of 120 elderly patients with LAA and stroke admitted to the hospital were retrospectively enrolled between September 2021 and September 2022. According to different treatment methods, they were divided into control group (56 cases, edaravone dexborneol) and observation group (64 cases, edaravone dexborneol combined with butylphthalide). The clinical curative effect in both groups was observed. The changes in nerve function [National Institutes of Health Stroke Scale (NIHSS), central nervous system-specific protein (S-100β), neuron-specific enolase (NSE)], inflammation factors (PTX3, lp-PLA2) and positive rate of MES before and after treatment were compared between the two groups. The occurrence of adverse reactions was recorded. Results: The response rate of treatment in observation group was higher than that in control group (95.31% vs 78.57%) (χ²=7.653, P=0.006). After treatment, NIHSS score, S-100β and NSE levels in observation group were lower than those in control group (P<0.05), levels of PTX3 and lp-PLA2, and positive rate of MES were lower than those in control group (P<0.05). There was no significant difference in the total incidence of adverse reactions between observation group and control group (6.25% vs 5.36%) (Fisher=1.000). Conclusion: Edaravone dexborneol combined with butylphthalide can effectively improve the clinical efficacy, promote the recovery of neurological function, reduce the levels of PTX3, lp-PLA2 and the positive rate of MES in elderly patients with LAA, and control the development of the disease, with good safety.
- Subjects
PHOSPHOLIPASE A2; OLDER patients; NATIONAL Institutes of Health (U.S.); EDARAVONE; CONTROL groups; ENOLASE
- Publication
Progress in Modern Biomedicine, 2023, Vol 23, Issue 12, p2392
- ISSN
1673-6273
- Publication type
Article
- DOI
10.13241/j.cnki.pmb.2023.12.036